NCT04458259 2025-08-28Study of PF-07265807 in Participants With Metastatic Solid Tumors.PfizerPhase 1 Terminated88 enrolled
NCT02912572 2025-07-10Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerDana-Farber Cancer InstitutePhase 2 Active not recruiting106 enrolled 16 charts
NCT04197219 2020-11-05Pembrolizumab With Axitinib in Recurrent Endometrial CancerCase Comprehensive Cancer CenterPhase 2 Withdrawn